The Roche Group is forecasting stable to modest sales growth this year as it transitions to new leadership and continues to launch more products to offset the impact of biosimilar competition for its legacy medicines. Severin Schwan, chief executive since 2008, will step down from his post on 14 March 2023 and be succeeded by Thomas Schinecker, currently CEO of the diagnostics division. Dr Schwan is to be nominated as chairman of the company’s board of directors.
